Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

BACKGROUND: OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1–3 h and secondary tumour cell necrosis between 6 and 72 h. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, M R, Ward, T, Dive, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364117/
https://www.ncbi.nlm.nih.gov/pubmed/22538971
http://dx.doi.org/10.1038/bjc.2012.165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364117/
https://www.ncbi.nlm.nih.gov/pubmed/22538971
http://dx.doi.org/10.1038/bjc.2012.165

Ejemplares similares